* Menarini Group and NewAmsterdam Pharma receive European Commission approval for **Ubeslo®** (obicetrapib monotherapy) and **Evlarco®** (obicetrapib plus ezetimibe fixed-dose combination). Source text: ID:nPreFkwDLa Further company coverage: KH6.F
NAMS•
